|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Rumgay H, Arnold M, Ferlay J, Lesi O,
Cabasag CJ, Vignat J, Laversanne M, McGlynn KA and Soerjomataram I:
Global burden of primary liver cancer in 2020 and predictions to
2040. J Hepatol. 77:1598–1606. 2022. View Article : Google Scholar
|
|
3
|
Qin S, Bai Y, Lim HY, Thongprasert S, Chao
Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, et al:
Randomized, multicenter, open-label study of oxaliplatin plus
fluorouracil/leucovorin versus doxorubicin as palliative
chemotherapy in patients with advanced hepatocellular carcinoma
from Asia. J Clin Oncol. 31:3501–3508. 2013. View Article : Google Scholar
|
|
4
|
Donne R and Lujambio A: The liver cancer
immune microenvironment: Therapeutic implications for
hepatocellular carcinoma. Hepatology. 77:1773–1796. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu AX, Finn RS, Edeline J, Cattan S,
Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A,
et al: Treated Pembrolizumab in patients with advanced
hepatocellular carcinoma previously with sorafenib (KEYNOTE-224): A
non-randomised, open-label phase 2 trial. Lancet Oncol. 19:940–952.
2018. View Article : Google Scholar
|
|
6
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al:
Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502. 2017.
View Article : Google Scholar
|
|
7
|
Giraud J, Chalopin D, Blanc JF and Saleh
M: Hepatocellular carcinoma immune landscape and the potential of
immunotherapies. Front Immunol. 12:6556972021. View Article : Google Scholar
|
|
8
|
Sharma A, Seow JJW, Dutertre CA, Pai R,
Blériot C, Mishra A, Wong RMM, Singh GSN, Sudhagar S, Khalilnezhad
S, et al: Onco-fetal reprogramming of endothelial cells drives
immunosuppressive macrophages in hepatocellular carcinoma. Cell.
183:377–394.e21. 2020. View Article : Google Scholar
|
|
9
|
Chen DS and Mellman I: Oncology meets
immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Khong HT and Restifo NP: Natural selection
of tumor variants in the generation of ‘tumor escape’ phenotypes.
Nat Immunol. 3:999–1005. 2002. View Article : Google Scholar
|
|
11
|
Thomas DA and Massagué J: TGF-beta
directly targets cytotoxic T cell functions during tumor evasion of
immune surveillance. Cancer Cell. 8:369–380. 2005. View Article : Google Scholar
|
|
12
|
Drake CG, Jaffee E and Pardoll DM:
Mechanisms of immune evasion by tumors. Adv Immunol. 90:51–81.
2006. View Article : Google Scholar
|
|
13
|
Chen C, Wang Z, Ding Y and Qin Y: Tumor
microenvironment-mediated immune evasion in hepatocellular
carcinoma. Front Immunol. 14:11333082023. View Article : Google Scholar
|
|
14
|
Korpela K and de Vos WM: Early life
colonization of the human gut: Microbes matter everywhere. Curr
Opin Microbiol. 44:70–78. 2018. View Article : Google Scholar
|
|
15
|
Korpela K, Helve O, Kolho KL, Saisto T,
Skogberg K, Dikareva E, Stefanovic V, Salonen A, Andersson S and de
Vos WM: Maternal fecal microbiota transplantation in cesarean-born
infants rapidly restores normal gut microbial development: A
proof-of-concept study. Cell. 183:324–334.e5. 2020. View Article : Google Scholar
|
|
16
|
Yoo JY, Groer M, Dutra SVO, Sarkar A and
McSkimming DI: Gut microbiota and immune system interactions.
Microorganisms. 8:15872020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lloyd-Price J, Mahurkar A, Rahnavard G,
Crabtree J, Orvis J, Hall AB, Brady A, Creasy HH, McCracken C,
Giglio MG, et al: Strains, functions and dynamics in the expanded
Human microbiome project. Nature. 550:61–66. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu J, Zhu P, Shi L, Gao N, Li Y, Shu C, Xu
Y, Yu Y, He J, Guo D, et al: Bifidobacterium longum promotes
postoperative liver function recovery in patients with
hepatocellular carcinoma. Cell Host Microbe. 32:131–144.e6. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chambers ES, Byrne CS, Rugyendo A,
Morrison DJ, Preston T, Tedford C, Bell JD, Thomas L, Akbar AN,
Riddell NE, et al: The effects of dietary supplementation with
inulin and inulin-propionate ester on hepatic steatosis in adults
with non-alcoholic fatty liver disease. Diabetes Obes Metab.
21:372–376. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Paul SB, Acharya SK, Gamanagatti SR,
Sreenivas V, Shalimar S and Gulati MS: Acetic acid versus
radiofrequency ablation for the treatment of hepatocellular
carcinoma: A randomized controlled trial. Diagn Interv Imaging.
101:101–110. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yin Y, Sichler A, Ecker J, Laschinger M,
Liebisch G, Höring M, Basic M, Bleich A, Zhang XJ, Kübelsbeck L, et
al: Gut microbiota promote liver regeneration through hepatic
membrane phospholipid biosynthesis. J Hepatol. 78:820–835. 2023.
View Article : Google Scholar
|
|
22
|
Zhang M, Huang X, Zhang Y, Yu M, Yuan X,
Xu Y, Ma L, Wang X and Xing H: Gut microbial metabolite butyrate
suppresses hepatocellular carcinoma growth via CXCL11-dependent
enhancement of natural killer cell infiltration. Gut Microbes.
17:25197062025. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Behary J, Amorim N, Jiang XT, Raposo A,
Gong L, McGovern E, Ibrahim R, Chu F, Stephens C, Jebeili H, et al:
Gut microbiota impact on the peripheral immune response in
non-alcoholic fatty liver disease related hepatocellular carcinoma.
Nat Commun. 12:1872021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hliwa A, Ramos-Molina B, Laski D, Mika A
and Sledzinski T: The role of fatty acids in non-alcoholic fatty
liver disease progression: An update. Int J Mol Sci. 22:69002021.
View Article : Google Scholar
|
|
25
|
Kalyanaraman B, Cheng G and Hardy M: The
role of short-chain fatty acids in cancer prevention and cancer
treatment. Arch Biochem Biophys. 761:1101722024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Garrett WS: Cancer and the microbiota.
Science. 348:80–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bultman SJ and Jobin C: Microbial-derived
butyrate: An oncometabolite or tumor-suppressive metabolite? Cell
Host Microbe. 16:143–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dalile B, Van Oudenhove L, Vervliet B and
Verbeke K: The role of short-chain fatty acids in
microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol.
16:461–478. 2019. View Article : Google Scholar
|
|
29
|
Mann ER, Lam YK and Uhlig HH: Short-chain
fatty acids: Linking diet, the microbiome and immunity. Nat Rev
Immunol. 24:577–595. 2024. View Article : Google Scholar
|
|
30
|
Garron ML and Henrissat B: The continuing
expansion of CAZymes and their families. Curr Opin Chem Biol.
53:82–87. 2019. View Article : Google Scholar
|
|
31
|
Albillos A, de Gottardi A and Rescigno M:
The gut-liver axis in liver disease: Pathophysiological basis for
therapy. J Hepatol. 72:558–577. 2020. View Article : Google Scholar
|
|
32
|
Xu Z, Jiang N, Xiao Y, Yuan K and Wang Z:
The role of gut microbiota in liver regeneration. Front Immunol.
13:10033762022. View Article : Google Scholar
|
|
33
|
Singh V, Lee G, Son H, Koh H, Kim ES, Unno
T and Shin JH: Butyrate producers, ‘The Sentinel of Gut’: Their
intestinal significance with and beyond butyrate, and prospective
use as microbial therapeutics. Front Microbiol. 13:11038362022.
View Article : Google Scholar
|
|
34
|
Schönfeld P and Wojtczak L: Short- and
medium-chain fatty acids in energy metabolism: The cellular
perspective. J Lipid Res. 57:943–954. 2016. View Article : Google Scholar
|
|
35
|
Deleu S, Machiels K, Raes J, Verbeke K and
Vermeire S: Short chain fatty acids and its producing organisms: An
overlooked therapy for IBD? EBioMedicine. 66:1032932021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rooks MG and Garrett WS: Gut microbiota,
metabolites and host immunity. Nat Rev Immunol. 16:341–352. 2016.
View Article : Google Scholar
|
|
37
|
Wong JM, de Souza R, Kendall CW, Emam A
and Jenkins DJ: Colonic health: Fermentation and short chain fatty
acids. J Clin Gastroenterol. 40:235–243. 2006. View Article : Google Scholar
|
|
38
|
Martin-Gallausiaux C, Marinelli L,
Blottière HM, Larraufie P and Lapaque N: SCFA: Mechanisms and
functional importance in the gut. Proc Nutr Soc. 80:37–49. 2021.
View Article : Google Scholar
|
|
39
|
Frankel WL, Zhang W, Singh A, Klurfeld DM,
Don S, Sakata T, Modlin I and Rombeau JL: Mediation of the trophic
effects of short-chain fatty acids on the rat jejunum and colon.
Gastroenterology. 106:375–380. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Brown AJ, Goldsworthy SM, Barnes AA,
Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, Kinghorn
I, Fraser NJ, et al: The Orphan G protein-coupled receptors GPR41
and GPR43 are activated by propionate and other short chain
carboxylic acids. J Biol Chem. 278:11312–11319. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Thangaraju M, Cresci GA, Liu K, Ananth S,
Gnanaprakasam JP, Browning DD, Mellinger JD, Smith SB, Digby GJ,
Lambert NA, et al: GPR109A is a G-protein-coupled receptor for the
bacterial fermentation product butyrate and functions as a tumor
suppressor in colon. Cancer Res. 69:2826–2832. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hou J: Drinking vinegar, a potential
adjuvant for immunotherapy of HCC? Hepatology. 77:3–5. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tan JK, McKenzie C, Mariño E, Macia L and
Mackay CR: Metabolite-Sensing G protein-coupled
receptors-facilitators of diet-related immune regulation. Annu Rev
Immunol. 35:371–402. 2017. View Article : Google Scholar
|
|
44
|
Li S, Duan Y, Luo S, Zhou F, Wu Q and Lu
Z: Short-chain fatty acids and cancer. Trends Cancer. 11:154–168.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang X, Coker OO, Chu ES, Fu K, Lau HCH,
Wang YX, Chan AWH, Wei H, Yang X, Sung JJY and Yu J: Dietary
cholesterol drives fatty liver-associated liver cancer by
modulating gut microbiota and metabolites. Gut. 70:761–774. 2021.
View Article : Google Scholar
|
|
46
|
Zhao S, Zhang H, Zhu H, Zhao T, Tu J, Yin
X, Yang S, Zhang W, Zhang F, Zhang M, et al: Gut microbiota
promotes macrophage M1 polarization in hepatic sinusoidal
obstruction syndrome via regulating intestinal barrier function
mediated by butyrate. Gut Microbes. 16:23775672024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Deng M, Qu F, Chen L, Liu C, Zhang M, Ren
F, Guo H, Zhang H, Ge S, Wu C and Zhao L: SCFAs alleviated
steatosis and inflammation in mice with NASH induced by MCD. J
Endocrinol. 245:425–437. 2020. View Article : Google Scholar
|
|
48
|
Tilg H, Adolph TE and Trauner M: Gut-liver
axis: Pathophysiological concepts and clinical implications. Cell
Metab. 34:1700–1718. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Turner JR: Intestinal mucosal barrier
function in health and disease. Nat Rev Immunol. 9:799–809. 2009.
View Article : Google Scholar
|
|
50
|
Abreu MT: Toll-like receptor signalling in
the intestinal epithelium: how bacterial recognition shapes
intestinal function. Nat Rev Immunol. 10:131–144. 2010. View Article : Google Scholar
|
|
51
|
Balmer ML, Slack E, de Gottardi A, Lawson
MA, Hapfelmeier S, Miele L, Grieco A, Van Vlierberghe H, Fahrner R,
Patuto N, et al: The liver may act as a firewall mediating
mutualism between the host and its gut commensal microbiota. Sci
Transl Med. 6:237ra662014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rui L: Energy metabolism in the liver.
Compr Physiol. 4:177–197. 2014. View Article : Google Scholar
|
|
53
|
Sahuri-Arisoylu M, Brody LP, Parkinson JR,
Parkes H, Navaratnam N, Miller AD, Thomas EL, Frost G and Bell JD:
Reprogramming of hepatic fat accumulation and ‘browning’ of adipose
tissue by the short-chain fatty acid acetate. Int J Obes (Lond).
40:955–963. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Karpe AV, Hutton ML, Mileto SJ, James ML,
Evans C, Ghodke AB, Shah RM, Metcalfe SS, Liu JW, Walsh T, et al:
Gut microbial perturbation and host response induce redox pathway
upregulation along the gut-liver axis during giardiasis in C57BL/6J
mouse model. Int J Mol Sci. 24:16362023. View Article : Google Scholar
|
|
55
|
Wang X, Zhang B and Jiang R: Microbiome
interplays in the gut-liver axis: implications for liver cancer
pathogenesis and therapeutic insights. Front Cell Infect Microbiol.
15:14671972025. View Article : Google Scholar
|
|
56
|
den Besten G, Bleeker A, Gerding A, van
Eunen K, Havinga R, van Dijk TH, Oosterveer MH, Jonker JW, Groen
AK, Reijngoud DJ and Bakker BM: Short-chain fatty acids protect
against high-fat diet-induced obesity via a PPARγ-Dependent switch
from lipogenesis to fat oxidation. Diabetes. 64:2398–2408. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Pavlova NN and Thompson CB: The emerging
hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar
|
|
59
|
Park S and Hall MN: Metabolic
reprogramming in hepatocellular carcinoma: Mechanisms and
therapeutic implications. Exp Mol Med. 57:515–523. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Golonka RM and Vijay-Kumar M: Atypical
immunometabolism and metabolic reprogramming in liver cancer:
Deciphering the role of gut microbiome. Adv Cancer Res.
149:171–255. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Cao Q, Yang M and Chen M: Metabolic
interactions: how gut microbial metabolites influence colorectal
cancer. Front Microbiol. 16:16116982025. View Article : Google Scholar
|
|
63
|
Jang C, Hui S, Lu W, Cowan AJ, Morscher
RJ, Lee G, Liu W, Tesz GJ, Birnbaum MJ and Rabinowitz JD: The small
intestine converts dietary fructose into glucose and organic acids.
Cell Metab. 27:351–361.e3. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Astbury S, Song A, Zhou M, Nielsen B,
Hoedl A, Willing BP, Symonds ME and Bell RC: High fructose intake
during pregnancy in rats influences the maternal microbiome and gut
development in the offspring. Front Genet. 9:2032018. View Article : Google Scholar
|
|
65
|
Song M, Li X, Zhang X, Shi H, Vos MB, Wei
X, Wang Y, Gao H, Rouchka EC, Yin X, et al: Dietary copper-fructose
interactions alter gut microbial activity in male rats. Am J
Physiol Gastrointest Liver Physiol. 314:G119–G130. 2018. View Article : Google Scholar
|
|
66
|
Dewdney B, Roberts A, Qiao L, George J and
Hebbard L: A sweet connection? Fructose's role in hepatocellular
carcinoma. Biomolecules. 10:4962020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Jang C, Wada S, Yang S, Gosis B, Zeng X,
Zhang Z, Shen Y, Lee G, Arany Z and Rabinowitz JD: The small
intestine shields the liver from fructose-induced steatosis. Nat
Metab. 2:586–593. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Li L, Che L, Tharp KM, Park HM, Pilo MG,
Cao D, Cigliano A, Latte G, Xu Z, Ribback S, et al: Differential
requirement for de novo lipogenesis in cholangiocarcinoma and
hepatocellular carcinoma of mice and humans. Hepatology.
63:1900–1913. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Nelson ME, Lahiri S, Chow JD, Byrne FL,
Hargett SR, Breen DS, Olzomer EM, Wu LE, Cooney GJ, Turner N, et
al: Inhibition of hepatic lipogenesis enhances liver tumorigenesis
by increasing antioxidant defence and promoting cell survival. Nat
Commun. 8:146892017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Gao Q, Zhang G, Zheng Y, Yang Y, Chen C,
Xia J, Liang L, Lei C, Hu Y, Cai X, et al: SLC27A5 deficiency
activates NRF2/TXNRD1 pathway by increased lipid peroxidation in
HCC. Cell Death Differ. 27:1086–1104. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Canfora EE, Meex RCR, Venema K and Blaak
EE: Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev
Endocrinol. 15:261–273. 2019. View Article : Google Scholar
|
|
72
|
Paul B, Lewinska M and Andersen JB: Lipid
alterations in chronic liver disease and liver cancer. JHEP Rep.
4:1004792022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Lau HC, Zhang X and Yu J: Gut microbiome
in metabolic dysfunction-associated steatotic liver disease and
associated hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol.
22:619–638. 2025. View Article : Google Scholar
|
|
74
|
Atarashi K, Tanoue T, Oshima K, Suda W,
Nagano Y, Nishikawa H, Fukuda S, Saito T, Narushima S, Hase K, et
al: Treg induction by a rationally selected mixture of Clostridia
strains from the human microbiota. Nature. 500:232–236. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Narushima S, Sugiura Y, Oshima K, Atarashi
K, Hattori M, Suematsu M and Honda K: Characterization of the 17
strains of regulatory T cell-inducing human-derived Clostridia. Gut
Microbes. 5:333–339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Scheiman J, Luber JM, Chavkin TA,
MacDonald T, Tung A, Pham LD, Wibowo MC, Wurth RC, Punthambaker S,
Tierney BT, et al: Meta-omics analysis of elite athletes identifies
a performance-enhancing microbe that functions via lactate
metabolism. Nat Med. 25:1104–1109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Comerford SA, Huang Z, Du X, Wang Y, Cai
L, Witkiewicz AK, Walters H, Tantawy MN, Fu A, Manning HC, et al:
Acetate dependence of tumors. Cell. 159:1591–1602. 2014. View Article : Google Scholar
|
|
78
|
Lin J, Rao D, Zhang M and Gao Q: Metabolic
reprogramming in the tumor microenvironment of liver cancer. J
Hematol Oncol. 17:62024. View Article : Google Scholar
|
|
79
|
Song Y, Lau HC, Zhang X and Yu J: Bile
acids, gut microbiota, and therapeutic insights in hepatocellular
carcinoma. Cancer Biol Med. 21:144–162. 2023.PubMed/NCBI
|
|
80
|
Han J, Qin WX, Li ZL, Xu AJ, Xing H, Wu H,
Zhang H, Wang MD, Li C, Liang L, et al: Tissue and serum metabolite
profiling reveals potential biomarkers of human hepatocellular
carcinoma. Clin Chim Acta. 488:68–75. 2019. View Article : Google Scholar
|
|
81
|
Sun Y, Zhu M, Zhao H, Ni X, Chang R, Su J,
Huang H, Cui S, Wang X, Yuan J, et al: Serum fibroblast growth
factor 19 and total bile acid concentrations are potential
biomarkers of hepatocellular carcinoma in patients with type 2
diabetes mellitus. Biomed Res Int. 2020:17519892020. View Article : Google Scholar
|
|
82
|
Colosimo S and Tomlinson JW: Bile acids as
drivers and biomarkers of hepatocellular carcinoma. World J
Hepatol. 14:1730–1738. 2022. View Article : Google Scholar
|
|
83
|
Chiu M, Tardito S, Pillozzi S, Arcangeli
A, Armento A, Uggeri J, Missale G, Bianchi MG, Barilli A, Dall'Asta
V, et al: Glutamine depletion by crisantaspase hinders the growth
of human hepatocellular carcinoma xenografts. Br J Cancer.
111:1159–1167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Jin L, Alesi GN and Kang S: Glutaminolysis
as a target for cancer therapy. Oncogene. 35:3619–3625. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Sun HW, Yu XJ, Wu WC, Chen J, Shi M, Zheng
L and Xu J: GLUT1 and ASCT2 as predictors for prognosis of
hepatocellular carcinoma. PLoS One. 11:e01689072016. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Adebayo Michael AO, Ko S, Tao J, Moghe A,
Yang H, Xu M, Russell JO, Pradhan-Sundd T, Liu S, Singh S, et al:
Inhibiting glutamine-dependent mTORC1 activation ameliorates liver
cancers driven by β-catenin mutations. Cell Metab. 29:1135–1150.e6.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Wei Y, Tang X, Ren Y, Yang Y, Song F, Fu
J, Liu S, Yu M, Chen J, Wang S, et al: An RNA-RNA crosstalk network
involving HMGB1 and RICTOR facilitates hepatocellular carcinoma
tumorigenesis by promoting glutamine metabolism and impedes
immunotherapy by PD-L1+ exosomes activity. Signal Transduct Target
Ther. 6:4212021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Huang X, Gan G, Wang X, Xu T and Xie W:
The HGF-MET axis coordinates liver cancer metabolism and autophagy
for chemotherapeutic resistance. Autophagy. 15:1258–1279. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Klement RJ: Beneficial effects of
ketogenic diets for cancer patients: A realist review with focus on
evidence and confirmation. Med Oncol. 34:1322017. View Article : Google Scholar
|
|
90
|
Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong
T, Chen H and Wang C: Immunotherapy: Reshape the tumor immune
microenvironment. Front Immunol. 13:8441422022. View Article : Google Scholar
|
|
91
|
Ringelhan M, Pfister D, O'Connor T,
Pikarsky E and Heikenwalder M: The immunology of hepatocellular
carcinoma. Nat Immunol. 19:222–232. 2018. View Article : Google Scholar
|
|
92
|
Zheng M and Tian Z: Liver-mediated
adaptive immune tolerance. Front Immunol. 10:25252019. View Article : Google Scholar
|
|
93
|
Vinolo MA, Rodrigues HG, Nachbar RT and
Curi R: Regulation of inflammation by short chain fatty acids.
Nutrients. 3:858–876. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Hao X, Sun G, Zhang Y, Kong X, Rong D,
Song J, Tang W and Wang X: Targeting immune cells in the tumor
microenvironment of HCC: New opportunities and challenges. Front
Cell Dev Biol. 9:7754622021. View Article : Google Scholar
|
|
95
|
Schwabe RF and Greten TF: Gut microbiome
in HCC-Mechanisms, diagnosis and therapy. J Hepatol. 72:230–238.
2020. View Article : Google Scholar
|
|
96
|
Yu LX and Schwabe RF: The gut microbiome
and liver cancer: Mechanisms and clinical translation. Nat Rev
Gastroenterol Hepatol. 14:527–539. 2017. View Article : Google Scholar
|
|
97
|
Ma C, Han M, Heinrich B, Fu Q, Zhang Q,
Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, et al: Gut
microbiome-mediated bile acid metabolism regulates liver cancer via
NKT cells. Science. 360:eaan59312018. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Luu M, Riester Z, Baldrich A, Reichardt N,
Yuille S, Busetti A, Klein M, Wempe A, Leister H, Raifer H, et al:
Microbial short-chain fatty acids modulate CD8(+) T cell responses
and improve adoptive immunotherapy for cancer. Nat Commun.
12:40772021. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Bloemen JG, Venema K, van de Poll MC, Olde
Damink SW, Buurman WA and Dejong CH: Short chain fatty acids
exchange across the gut and liver in humans measured at surgery.
Clin Nutr. 28:657–661. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ren Z, Li A, Jiang J, Zhou L, Yu Z, Lu H,
Xie H, Chen X, Shao L, Zhang R, et al: Gut microbiome analysis as a
tool towards targeted non-invasive biomarkers for early
hepatocellular carcinoma. Gut. 68:1014–1023. 2019. View Article : Google Scholar
|
|
101
|
Lapidot Y, Amir A, Nosenko R, Uzan-Yulzari
A, Veitsman E, Cohen-Ezra O, Davidov Y, Weiss P, Bradichevski T,
Segev S, et al: Alterations in the gut microbiome in the
progression of cirrhosis to hepatocellular carcinoma. mSystems.
5:e001532020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Song Q, Zhang X, Liu W, Wei H, Liang W,
Zhou Y, Ding Y, Ji F, Ho-Kwan Cheung A, Wong N and Yu J:
Bifidobacterium pseudolongum-generated acetate suppresses
non-alcoholic fatty liver disease-associated hepatocellular
carcinoma. J Hepatol. 79:1352–1365. 2023. View Article : Google Scholar
|
|
103
|
Kobayashi M, Mikami D, Uwada J, Yazawa T,
Kamiyama K, Kimura H, Taniguchi T and Iwano M: A short-chain fatty
acid, propionate, enhances the cytotoxic effect of cisplatin by
modulating GPR41 signaling pathways in HepG2 cells. Oncotarget.
9:31342–31354. 2018. View Article : Google Scholar
|
|
104
|
Hu Y, Setayesh T, Vaziri F, Wu X, Hwang
ST, Chen X and Yvonne Wan YJ: miR-22 gene therapy treats HCC by
promoting anti-tumor immunity and enhancing metabolism. Mol Ther.
31:1829–1845. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Ma H, Yang L, Liang Y, Liu F, Hu J, Zhang
R, Li Y, Yuan L and Feng F: B. thetaiotaomicron-derived acetic acid
modulate immune microenvironment and tumor growth in hepatocellular
carcinoma. Gut Microbes. 16:22978462024. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Mohebali N, Weigel M, Hain T, Sütel M,
Bull J, Kreikemeyer B and Breitrück A: Faecalibacterium
prausnitzii, Bacteroides faecis and Roseburia intestinalis
attenuate clinical symptoms of experimental colitis by regulating
Treg/Th17 cell balance and intestinal barrier integrity. Biomed
Pharmacother. 167:1155682023. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Yang J, Gao H, Zhang T, Fan Y, Wu Y, Zhao
X, Li Y, Wu L, Zhao H, Yang L, et al: In vitro lactic acid bacteria
anti-hepatitis B virus (HBV) effect and modulation of the
intestinal microbiota in fecal cultures from HBV-Associated
hepatocellular carcinoma patients. Nutrients. 16:6002024.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Honda T, Ishigami M, Ishizu Y, Imai N, Ito
T, Yamamoto K, Yokoyama S, Muto H, Inukai Y, Kato A, et al: Gut
microbes associated with functional cure of chronic hepatitis B.
Hepatol Int. 19:519–528. 2025. View Article : Google Scholar
|
|
109
|
Kim MH, Kang SG, Park JH, Yanagisawa M and
Kim CH: Short-chain fatty acids activate GPR41 and GPR43 on
intestinal epithelial cells to promote inflammatory responses in
mice. Gastroenterology. 145:396–406.e1-10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Belcheva A, Irrazabal T, Robertson SJ,
Streutker C, Maughan H, Rubino S, Moriyama EH, Copeland JK,
Surendra A, Kumar S, et al: Gut microbial metabolism drives
transformation of MSH2-deficient colon epithelial cells. Cell.
158:288–299. 2014. View Article : Google Scholar
|
|
111
|
Singh V, Chassaing B, Zhang L, San Yeoh B,
Xiao X, Kumar M, Baker MT, Cai J, Walker R, Borkowski K, et al:
Microbiota-dependent hepatic lipogenesis mediated by stearoyl CoA
Desaturase 1 (SCD1) promotes metabolic syndrome in TLR5-deficient
mice. Cell Metab. 22:983–996. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Singh V, Yeoh BS, Chassaing B, Xiao X,
Saha P, Aguilera Olvera R, Lapek JD Jr, Zhang L, Wang WB, Hao S, et
al: Dysregulated microbial fermentation of soluble fiber induces
cholestatic liver cancer. Cell. 175:679–694.e22. 2018. View Article : Google Scholar
|
|
113
|
Rajapakse J, Khatiwada S, Akon AC, Yu KL,
Shen S and Zekry A: Unveiling the complex relationship between gut
microbiota and liver cancer: Opportunities for novel therapeutic
interventions. Gut Microbes. 15:22400312023. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Wang Y, Li Y, Lin Y, Cao C, Chen D, Huang
X, Li C, Xu H, Lai H, Chen H and Zhou Y: Roles of the gut
microbiota in hepatocellular carcinoma: From the gut dysbiosis to
the intratumoral microbiota. Cell Death Discov. 11:1402025.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Dupraz L, Magniez A, Rolhion N, Richard
ML, Da Costa G, Touch S, Mayeur C, Planchais J, Agus A, Danne C, et
al: Gut microbiota-derived short-chain fatty acids regulate IL-17
production by mouse and human intestinal γδ T cells. Cell Rep.
36:1093322021. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Zhou P, Chang WY, Gong DA, Xia J, Chen W,
Huang LY, Liu R, Liu Y, Chen C, Wang K, et al: High dietary
fructose promotes hepatocellular carcinoma progression by enhancing
O-GlcNAcylation via microbiota-derived acetate. Cell Metab.
35:1961–1975.e6. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Zhao S, Jang C, Liu J, Uehara K, Gilbert
M, Izzo L, Zeng X, Trefely S, Fernandez S, Carrer A, et al: Dietary
fructose feeds hepatic lipogenesis via microbiota-derived acetate.
Nature. 579:586–591. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Wang J, Yang Y, Shao F, Meng Y, Guo D, He
J and Lu Z: Acetate reprogrammes tumour metabolism and promotes
PD-L1 expression and immune evasion by upregulating c-Myc. Nat
Metab. 6:914–932. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Sun M, Wu W, Chen L, Yang W, Huang X, Ma
C, Chen F, Xiao Y, Zhao Y, Ma C, et al: Microbiota-derived
short-chain fatty acids promote Th1 cell IL-10 production to
maintain intestinal homeostasis. Nat Commun. 9:35552018. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Chang PV, Hao L, Offermanns S and
Medzhitov R: The microbial metabolite butyrate regulates intestinal
macrophage function via histone deacetylase inhibition. Proc Natl
Acad Sci USA. 111:2247–2252. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Yeoh BS, Saha P, Golonka RM, Zou J,
Petrick JL, Abokor AA, Xiao X, Bovilla VR, Bretin ACA,
Rivera-Esteban J, et al: Enterohepatic shunt-driven cholemia
predisposes to liver cancer. Gastroenterology. 163:1658–1671.e16.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Singh V, Yeoh BS, Abokor AA, Golonka RM,
Tian Y, Patterson AD, Joe B, Heikenwalder M and Vijay-Kumar M:
Vancomycin prevents fermentable fiber-induced liver cancer in mice
with dysbiotic gut microbiota. Gut Microbes. 11:1077–1091. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Zekry A and El-Omar EM: A tale of two
fibers: A liver twist! Gastroenterology. 163:1495–1497. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Arpaia N, Campbell C, Fan X, Dikiy S, van
der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ and
Rudensky AY: Metabolites produced by commensal bacteria promote
peripheral regulatory T-cell generation. Nature. 504:451–455. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Smith PM, Howitt MR, Panikov N, Michaud M,
Gallini CA, Bohlooly-Y M, Glickman JN and Garrett WS: The microbial
metabolites, short-chain fatty acids, regulate colonic Treg cell
homeostasis. Science. 341:569–573. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B,
Zhang Z, Yang H, Zhang H, Zhou C, et al: Increased regulatory T
cells correlate with CD8 T-cell impairment and poor survival in
hepatocellular carcinoma patients. Gastroenterology. 132:2328–2339.
2017. View Article : Google Scholar
|
|
127
|
Samuel BS, Shaito A, Motoike T, Rey FE,
Backhed F, Manchester JK, Hammer RE, Williams SC, Crowley J,
Yanagisawa M and Gordon JI: Effects of the gut microbiota on host
adiposity are modulated by the short-chain fatty-acid binding G
protein-coupled receptor, Gpr41. Proc Natl Acad Sci USA.
105:16767–16772. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Bjursell M, Admyre T, Göransson M, Marley
AE, Smith DM, Oscarsson J and Bohlooly-Y M: Improved glucose
control and reduced body fat mass in free fatty acid receptor
2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol
Metab. 300:E211–E220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Hu M, Eviston D, Hsu P, Mariño E, Chidgey
A, Santner-Nanan B, Wong K, Richards JL, Yap YA, Collier F, et al:
Decreased maternal serum acetate and impaired fetal thymic and
regulatory T cell development in preeclampsia. Nat Commun.
10:30312019. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Mariño E, Richards JL, McLeod KH, Stanley
D, Yap YA, Knight J, McKenzie C, Kranich J, Oliveira AC, Rossello
FJ, et al: Gut microbial metabolites limit the frequency of
autoimmune T cells and protect against type 1 diabetes. Nat
Immunol. 18:552–562. 2017. View Article : Google Scholar
|
|
131
|
Park J, Kim M, Kang SG, Jannasch AH,
Cooper B, Patterson J and Kim CH: Short-chain fatty acids induce
both effector and regulatory T cells by suppression of histone
deacetylases and regulation of the mTOR-S6K pathway. Mucosal
Immunol. 8:80–93. 2015. View Article : Google Scholar
|
|
132
|
Mandaliya DK, Patel S and Seshadri S: the
combinatorial effect of acetate and propionate on high-fat diet
induced diabetic inflammation or metaflammation and T cell
polarization. Inflammation. 44:68–79. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Hu C, Xu B, Wang X, Wan WH, Lu J, Kong D,
Jin Y, You W, Sun H, Mu X, et al: Gut microbiota-derived
short-chain fatty acids regulate group 3 innate lymphoid cells in
HCC. Hepatology. 77:48–64. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Zhou CJ, Xie BL, Han HY, Wang Y, Wang YH,
Hong JY, Wei YX, Liu ZG, Feng Y, Yang G and Yang PC: Short-chain
fatty acids promote immunotherapy by modulating immune regulatory
property in B cells. J Immunol Res. 2021:26843612021. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Bachem A, Makhlouf C, Binger KJ, de Souza
DP, Tull D, Hochheiser K, Whitney PG, Fernandez-Ruiz D, Dähling S,
Kastenmüller W, et al: Microbiota-derived short-chain fatty acids
promote the memory potential of antigen-activated CD8(+) T cells.
Immunity. 51:285–297.e5. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Kang X, Liu C, Ding Y, Ni Y, Ji F, Lau
HCH, Jiang L, Sung JJ, Wong SH and Yu J: Roseburia intestinalis
generated butyrate boosts anti-PD-1 efficacy in colorectal cancer
by activating cytotoxic CD8(+) T cells. Gut. 72:2112–2122. 2023.
View Article : Google Scholar
|
|
137
|
Yang W, Yu T, Huang X, Bilotta AJ, Xu L,
Lu Y, Sun J, Pan F, Zhou J, Zhang W, et al: Intestinal
microbiota-derived short-chain fatty acids regulation of immune
cell IL-22 production and gut immunity. Nat Commun. 11:44572020.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Huang C, Du W, Ni Y, Lan G and Shi G: The
effect of short-chain fatty acids on M2 macrophages polarization in
vitro and in vivo. Clin Exp Immunol. 207:53–64. 2022. View Article : Google Scholar
|
|
139
|
Schulthess J, Pandey S, Capitani M,
Rue-Albrecht KC, Arnold I, Franchini F, Chomka A, Ilott NE,
Johnston DGW, Pires E, et al: The short chain fatty acid butyrate
imprints an antimicrobial program in macrophages. Immunity.
50:432–445.e7. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Luu M, Weigand K, Wedi F, Breidenbend C,
Leister H, Pautz S, Adhikary T and Visekruna A: Regulation of the
effector function of CD8(+) T cells by gut microbiota-derived
metabolite butyrate. Sci Rep. 8:144302018. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Chriett S, Dąbek A, Wojtala M, Vidal H,
Balcerczyk A and Pirola L: Prominent action of butyrate over
β-hydroxybutyrate as histone deacetylase inhibitor, transcriptional
modulator and anti-inflammatory molecule. Sci Rep. 9:7422019.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Gao Q, Wei A, Chen F, Chen X, Ding W, Ding
Z, Wu Z, Du R and Cao W: Enhancing PPARγ by HDAC inhibition reduces
foam cell formation and atherosclerosis in ApoE deficient mice.
Pharmacol Res. 160:1050592020. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Sun B, Jia Y, Hong J, Sun Q, Gao S, Hu Y,
Zhao N and Zhao R: Sodium butyrate ameliorates
high-fat-diet-induced non-alcoholic fatty liver disease through
peroxisome proliferator-activated receptor α-mediated activation of
β oxidation and suppression of inflammation. J Agric Food Chem.
66:7633–7642. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
van Vorstenbosch R, Cheng HR, Jonkers D,
Penders J, Schoon E, Masclee A, van Schooten FJ, Smolinska A and
Mujagic Z: Systematic review: Contribution of the gut microbiome to
the volatile metabolic fingerprint of colorectal neoplasia.
Metabolites. 13:552022. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Loomba R, Seguritan V, Li W, Long T,
Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander
SK, et al: Gut microbiome-based metagenomic signature for
non-invasive detection of advanced fibrosis in human nonalcoholic
fatty liver disease. Cell Metab. 30:6072019. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Gopalakrishnan V, Spencer CN, Nezi L,
Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman
K, Wei SC, et al: Gut microbiome modulates response to anti-PD-1
immunotherapy in melanoma patients. Science. 359:97–103. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Nomura M, Nagatomo R, Doi K, Shimizu J,
Baba K, Saito T, Matsumoto S, Inoue K and Muto M: Association of
short-chain fatty acids in the gut microbiome with clinical
response to treatment with nivolumab or pembrolizumab in patients
with solid cancer tumors. JAMA Netw Open. 3:e2028952020. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Coutzac C, Jouniaux JM, Paci A, Schmidt J,
Mallardo D, Seck A, Asvatourian V, Cassard L, Saulnier P, Lacroix
L, et al: Systemic short chain fatty acids limit antitumor effect
of CTLA-4 blockade in hosts with cancer. Nat Commun. 11:21682020.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Oliver A, Alkan Z, Stephensen CB, Newman
JW, Kable ME and Lemay DG: Diet, microbiome, and inflammation
predictors of fecal and plasma short-chain fatty acids in humans. J
Nutr. 154:3298–3311. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Mirzaei R, Afaghi A, Babakhani S, Sohrabi
MR, Hosseini-Fard SR, Babolhavaeji K, Khani Ali Akbari S,
Yousefimashouf R and Karampoor S: Role of microbiota-derived
short-chain fatty acids in cancer development and prevention.
Biomed Pharmacother. 139:1116192021. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Polyviou T, MacDougall K, Chambers ES,
Viardot A, Psichas A, Jawaid S, Harris HC, Edwards CA, Simpson L,
Murphy KG, et al: Randomised clinical study: Inulin short-chain
fatty acid esters for targeted delivery of short-chain fatty acids
to the human colon. Aliment Pharmacol Ther. 44:662–672. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Yan J, Pan Y, Shao W, Wang C, Wang R, He
Y, Zhang M, Wang Y, Li T, Wang Z, et al: Beneficial effect of the
short-chain fatty acid propionate on vascular calcification through
intestinal microbiota remodelling. Microbiome. 10:1952022.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Edelman MJ, Bauer K, Khanwani S, Tait N,
Trepel J, Karp J, Nemieboka N, Chung EJ and Van Echo D: Clinical
and pharmacologic study of tributyrin: An oral butyrate prodrug.
Cancer Chemother Pharmacol. 51:439–444. 2003. View Article : Google Scholar
|
|
154
|
Donovan JD, Bauer L, Fahey GC Jr and Lee
Y: In vitro digestion and fermentation of microencapsulated
tributyrin for the delivery of butyrate. J Food Sci. 82:1491–1499.
2017. View Article : Google Scholar
|
|
155
|
Johnston CS, Kim CM and Buller AJ: Vinegar
improves insulin sensitivity to a high-carbohydrate meal in
subjects with insulin resistance or type 2 diabetes. Diabetes Care.
27:281–282. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Ostman E, Granfeldt Y, Persson L and
Björck I: Vinegar supplementation lowers glucose and insulin
responses and increases satiety after a bread meal in healthy
subjects. Eur J Clin Nutr. 59:983–988. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Corrocher R, Tedesco F, Rabusin P and De
Sandre G: Effect of human erythrocyte stromata on complement
activation. Br J Haematol. 29:235–241. 1975. View Article : Google Scholar
|
|
158
|
Wheeler JG, Bogle ML, Shema SJ, Shirrell
MA, Stine KC, Pittler AJ, Burks AW and Helm RM: Impact of dietary
yogurt on immune function. Am J Med Sci. 313:120–123. 1997.
View Article : Google Scholar
|
|
159
|
Gill PA, van Zelm MC, Muir JG and Gibson
PR: Review article: Short chain fatty acids as potential
therapeutic agents in human gastrointestinal and inflammatory
disorders. Aliment Pharmacol Ther. 48:15–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Wolever TM, ter Wal P, Spadafora P and
Robb P: Guar, but not psyllium, increases breath methane and serum
acetate concentrations in human subjects. Am J Clin Nutr.
55:719–722. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Rahat-Rozenbloom S, Fernandes J, Cheng J,
Gloor GB and Wolever TM: The acute effects of inulin and resistant
starch on postprandial serum short-chain fatty acids and
second-meal glycemic response in lean and overweight humans. Eur J
Clin Nutr. 71:227–233. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
McOrist AL, Miller RB, Bird AR, Keogh JB,
Noakes M, Topping DL and Conlon MA: Fecal butyrate levels vary
widely among individuals but are usually increased by a diet high
in resistant starch. J Nutr. 141:883–889. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Upadhyaya B, McCormack L, Fardin-Kia AR,
Juenemann R, Nichenametla S, Clapper J, Specker B and Dey M: Impact
of dietary resistant starch type 4 on human gut microbiota and
immunometabolic functions. Sci Rep. 6:287972016. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Venkataraman A, Sieber JR, Schmidt AW,
Waldron C, Theis KR and Schmidt TM: Variable responses of human
microbiomes to dietary supplementation with resistant starch.
Microbiome. 4:332016. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Zhang F, Lo EKK, Chen C, Lee JC,
Felicianna Ismaiah MJ, Leung HKM, Tsang DHL and El-Nezami H:
Probiotics mixture, prohep: A potential adjuvant for low-dose
sorafenib in metabolic dysfunction-associated steatotic liver
disease-associated hepatocellular carcinoma suppression through
modulating gut microbiota. Probiotics Antimicrob Proteins. May
23–2025.(Epub ahead of print). View Article : Google Scholar
|
|
166
|
Wang X, Liu X, Gong F, Jiang Y, Zhang C,
Zhou W and Zhang W: Targeting gut microbiota for diabetic
nephropathy treatment: Probiotics, dietary interventions, and fecal
microbiota transplantation. Front Endocrinol (Lausanne).
16:16219682025. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Xu Z, Li W, Dong X, Chen Y, Zhang D, Wang
J, Zhou L and He G: Precision medicine in colorectal cancer:
Leveraging multi-omics, spatial omics, and artificial intelligence.
Clin Chim Acta. 559:1196862024. View Article : Google Scholar
|
|
168
|
Qusty N, Sarhan A, Taha M, Alshanqiti A,
Almuteb AM, Alfaraidi AT, Alkhairi HA, Alzahrani MM, Alamry AHA,
Alomry TQB, et al: The role of gut microbiota in the efficacy and
side effect profile of biologic therapies for autoimmune diseases.
Cureus. 16:e711112024.PubMed/NCBI
|
|
169
|
Lindstad LJ, Lo G, Leivers S, Lu Z,
Michalak L, Pereira GV, Røhr ÅK, Martens EC, McKee LS, Louis P, et
al: Human gut faecalibacterium prausnitzii deploys a highly
efficient conserved system to cross-feed on β-mannan-derived
oligosaccharides. mBio. 12:e03628202021. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Guo C, Che X, Briese T, Ranjan A, Allicock
O, Yates RA, Cheng A, March D, Hornig M, Komaroff AL, et al:
Deficient butyrate-producing capacity in the gut microbiome is
associated with bacterial network disturbances and fatigue symptoms
in ME/CFS. Cell Host Microbe. 31:288–304.e8. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Fässler D, Heinken A and Hertel J:
Characterising functional redundancy in microbiome communities via
relative entropy. Comput Struct Biotechnol J. 27:1482–1497. 2025.
View Article : Google Scholar
|
